Delivering Transcutaneous Auricular Neurostimulation to Regulate Platelet Activity in Healthy Human Subjects
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hemostasis
- Sponsor
- Five Liters, Inc.
- Enrollment
- 25
- Locations
- 1
- Primary Endpoint
- Biomarker of hemostasis (tissue anti-thrombin (TAT) complex) in blood shed from fingerstick
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
This study is designed as a randomized, double-blind, sham-controlled, single-center research study in which healthy adults will be randomized 1:1 into one of two experimental groups, to receive transcutaneous auricular vagus nerve stimulation (taVNS) targeting either the auricular branch of the vagus nerve (ABVN) or tAN, which targets the ABVN and the auriculotemporal nerve (ATN):
- Group 1: Sham taVNS followed by active taVNS
- Group 2: Sham tAN followed by active tAN
Participants will receive 30 minutes of sham stimulation (taVNS or tAN), followed by active stimulation (taVNS or tAN). Blood biomarkers (local and systemic) will be measured before and at several timepoints after stimulation to measure the molecular and cellular effects of the device.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participant is between 18 and 65 years of age
- •Participant is English proficient
- •Participant is able to provide informed consent and function at an intellectual level sufficient for study requirements
Exclusion Criteria
- •Participant has a history of thrombocytopenia (platelet count \<100k)
- •Participant has reported coagulopathy (elevated prothrombin time (PT), elevated partial thromboplastin time (PTT), elevated activated clotting time (ACT))
- •Participant has internal bleeding, external bleeding, easy bruising
- •Participant has a history of abnormal bleeding or blood disorder, including anemia or anemia-related disorders
- •Participant has a history of coagulopathy, including hemophilia, stroke, pulmonary embolism, myocardial infarction, or deep vein thromboses
- •Participant has a history of conditions that can cause coagulopathic conditions, including atrial fibrillation, heart valve surgery or replacement, hip or knee replacement, or clotting disorders
- •Participants using coagulation- or platelet-modifying therapies such as clotting factor products, emicizumab, desmopressin acetate, epsilon amino caproic acid, heparin and its derivatives, argatroban, desirudin, bivalirudin, warfarin, dabigatran, apixaban, edoxaban, betrixaban, or aspirin
- •Participant has a history of chronic tobacco use or has ingested nicotine via smoking, vaping, smokeless tobacco, or nicotine patches in the past three months
- •Participant has consumed caffeine within the past 12 hours
- •Participant has received a blood transfusion within 30 days prior to study
Outcomes
Primary Outcomes
Biomarker of hemostasis (tissue anti-thrombin (TAT) complex) in blood shed from fingerstick
Time Frame: From collection up to 240 minutes, assessed upon receipt of assay results (up to one month)
Percent change in TAT levels in shed blood after active stimulation between groups (taVNS vs tAN)
Biomarkers of hemostasis (TAT complex, D-dimer, viscoelasticity, coagulation tests (prothrombin time (PT), partial thromboplastin time (PTT)) in circulating blood
Time Frame: From collection up to 240 minutes, assessed upon receipt of assay results (up to one month)
Percent change in coagulation biomarker levels in circulating blood after active stimulation between groups ( taVNS vs tAN)
Biomarkers of inflammation (tumor necrosis factor (TNF), and interleukin (IL)-1B and IL-6) in circulating whole blood stimulated ex vivo with lipopolysaccharide (LPS)
Time Frame: From collection up to 240 minutes, assessed upon receipt of assay results (up to one month)
Percent change in inflammation biomarker levels in LPS-stimulated whole blood after active stimulation between groups (taVNS vs tAN)